Core Insights - Thermo Fisher Scientific plans to sell part of its diagnostics business for $4 billion [1] Company Summary - The sale is part of Thermo Fisher's strategy to streamline operations and focus on core areas of growth [1] - The divestiture is expected to enhance the company's financial flexibility and allow for reinvestment in higher-growth segments [1] Industry Context - The diagnostics market is experiencing significant changes, with companies reassessing their portfolios to adapt to evolving healthcare demands [1] - This move reflects a broader trend in the industry where firms are divesting non-core assets to concentrate on more profitable areas [1]